Cardiac Lesion Found in 2-Month-Old Child

Poll

A 2-month-old child with a history of tuberous sclerosis presents with a cardiac lesion. After a biopsy is performed, what is your diagnosis?

A 2-month-old child with a history of tuberous sclerosis presents with a cardiac lesion. According to the pathology slide below, what is your diagnosis?

What is your diagnosis?

A. Gaucher’s disease
B. Fabry disease
C. Rhabdomyoma
D. Syphilis

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
young person with cancer
uterus
Related Content
Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.

Post-HSCT Defibrotide Does Not Reduce Sinusoidal Obstruction Syndrome

Russ Conroy
February 14th 2025
Article

Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.

Data from the phase 3 MSB-GVHD001 trial support the FDA approval of remestemcel-L in pediatric SR-aGVHD.

FDA Approves Remestemcel-L in Pediatric SR-aGVHD

Russ Conroy
December 18th 2024
Article

Data from the phase 3 MSB-GVHD001 trial support the FDA approval of remestemcel-L in pediatric SR-aGVHD.

The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.

FDA Expands Approval for Methotrexate in Pediatric ALL, pJIA Indications

Russ Conroy
October 29th 2024
Article

The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.

Investigators previously assessed treatment with opaganib in patients with advanced cholangiocarcinoma and prostate cancer.

Opaganib Earns FDA Orphan Drug Status in Neuroblastoma

Russ Conroy
August 27th 2024
Article

Investigators previously assessed treatment with opaganib in patients with advanced cholangiocarcinoma and prostate cancer.

Results from the phase 2 AGAVE-201 trial of axatilimab for patients with relapsed/refractory chronic GVHD support the FDA approval.

FDA OKs Axatilimab in Pediatric/Adult Chronic GVHD

Ariana Pelosci
August 14th 2024
Article

Results from the phase 2 AGAVE-201 trial of axatilimab for patients with relapsed/refractory chronic GVHD support the FDA approval.

Phase 1 data may support the potential activity and safety of VCN-01 among pediatric patients with refractory retinoblastoma.

VCN-01 Earns Rare FDA Pediatric Drug Status in Retinoblastoma

Russ Conroy
August 1st 2024
Article

Phase 1 data may support the potential activity and safety of VCN-01 among pediatric patients with refractory retinoblastoma.